SCOTTSDALE, AZ--(Marketwired - May 5, 2014) - AirWare Labs Corp. (OTCQB: AIRW) today announced its licensing agreement with Breathe Active, LLC for its AIR™ ALLERGY and SLEEP/SNORE medical devices will expand into Australia and New Zealand. An exclusive marketing and distribution relationship with Australia-based Brand Developers Limited will enable Breathe Active to offer their licensed products through a direct response television media campaign beginning this month.
Powered by AirWare's patented nasal dilator technology, the Breathe Active Allergy product is infused with an essential oil blend designed to reduce allergy symptoms, and the 3M filtration media blocks airborne allergens. Breathe Active's patented nasal dilator utilized in Sleep/Snore increases airflow for better breathing and has been clinically proven to reduce snoring.
Brand Developers Limited, Australia's leading direct response television company, has ordered 10,000 units of Allergy and Sleep/Snore products in preparation of the highly anticipated television campaign. Brand Developers Limited specializes in product development, infomercial shopping and multi-channel retail distribution in Australia and New Zealand.
"Confidence in the Allergy and Sleep/Snore products is evidenced by the much higher initial order than is typically the case for a first-run direct response campaign," said Jetimira Kaizu, Brand Developers Limited's U.S. Agent. "We are anticipating high demand for both products, as there is nothing like either available in the marketplace."
"We are very excited to introduce Allergy and Sleep/Snore to the Australian and New Zealand markets," said Kevin Shaughnessy, President and CEO of Breathe Active, LLC. "Our initial TV rollout in the U.S. has had a tremendous response, so we know there's a significant international market for effective, drug-free allergy and sleep aids and we are excited about expanding our longstanding partnership with Brand Developers Limited as they make these revolutionary products available to the consumers of Australia and New Zealand."
Euromonitor International reported that the market for cough, cold and allergy remedies in Australia generated A$483 million in 2012, up 4% from the previous year. In a separate report, Euromonitor found that sleeping aids generated A$14 million in sales in 2012, up 5% from the previous year.
"The success of the Breathe Active product line reflects reported increases in allergies and sleep disorders throughout the world," said Jeffrey Rassás, President and CEO of AirWare Labs. "We are proud that AirWare technology, which has improved the lives of millions of people in the U.S., will now help residents of Australia and New Zealand breathe better."
AirWare Labs recently announced production of a branded video featuring TV and movie personalities Vincent Kartheiser (of AMC's drama Mad Men) and Adam Herschman. The company also announced plans for a sales and manufacturing expansion into China and a licensing agreement with Breathe Active, LLC earlier this year. AIR® ALLERGY was selected as a 2014 Visionary Award Finalist for the VISION® Consumer Products Conference in Dallas, and in 2013 AirWare Labs announced a national rollout into 7,500 Walgreen's stores.
About AirWare Labs Corporation:
AirWare Labs Corp. [publicly traded as (OTCQB: AIRW)] provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs' products are marketed under the brand name of AIR®. AIR® products utilize an FDA approved medical grade silicone, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR® microstructure enhances normal nasal airflow with every breath -- clinically proven to deliver up to 40% more oxygen.
Some AIR® products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR® Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR® specialty products help provide and performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: http://www.airwarelabs.com or company information visit: http://airwarelabscorp.com.
Forward-Looking Statement: The statements in this press release regarding any implied or perceived benefits from the release by AirWare Labs Corp. of its AIR® products are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.